Atomoxetine is a nonstimulant medication used to treat attention-deficit/hyperactivity disorder (ADHD). Cytochrome P450 (CYP)2D6 polymorphisms influence the metabolism of atomoxetine thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for atomoxetine based on CYP2D6 genotype (updates at www.cpicpgx.org).
Bibliographical noteFunding Information:
This work was funded by the National Institutes of Health (NIH) for CPIC (R24GM115264; U24HG010135-01) and PharmGKB (R24GM61374), PharmVar (R24GM123930). Atomoxetine studies conducted by the authors (J.T.B., A.G., J.C.D., and J.S.L.) have been supported by R01HD058556 and U54HD090258.
© 2019 The Authors Clinical Pharmacology & Therapeutics © 2019 American Society for Clinical Pharmacology and Therapeutics